New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
10:11 EDTRVBD, HP, XLNX, PNM, LUFK, CY, ATML, CLF, GILD, TFM, O, GNC, CRK, HAL, EFX, PWER, MGM, FET, CRLOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Atmel (ATML) upgraded to Buy from Hold at Needham... Best Buy (BBY) upgraded to Overweight from Equal Weight at Barclays... Charles River Labs (CRL) upgraded to Buy from Hold at Jefferies... Comstock Resources (CRK) upgraded to Outperform from Market Perform at BMO Capital... Cypress Semiconductor (CY) upgraded to Buy from Hold at Needham... Forum Energy (FET) upgraded to Outperform from Market Perform at FBR Capital... GNC Holdings (GNC) upgraded to Buy from Neutral at Goldman... Lufkin (LUFK) upgraded to Outperform from Market Perform at Wells Fargo... MGM Resorts (MGM) upgraded to Outperform from Sector Perform at RBC Capital... Realty Income (O) upgraded to Buy from Neutral at BofA/Merrill... PNM Resources (PNM) upgraded to Buy from Hold at Jefferies... Power-One (PWER) upgraded to Strong Buy from Outperform at Raymond James... The Fresh Market (TFM) upgraded to Buy from Neutral at Goldman... Xilinx (XLNX) upgraded to Buy from Neutral at BofA/Merrill... Equifax (EFX) upgraded to Overweight from Equal Weight at Evercore... Best Buy (BBY) upgraded to Buy from Hold at Stifel Nicolaus... Gilead (GILD) upgraded to Outperform from Neutral at Credit Suisse... Helmerich & Payne (HP) upgraded to Overweight from Equal Weight at Stephens... Halliburton (HAL) upgraded to Overweight from Equal Weight at Stephens... Cliffs Natural (CLF) upgraded to Overweight from Neutral at JPMorgan... Riverbed (RVBD) upgraded to Strong Buy from Buy at Needham.
News For ATML;CRL;CRK;CY;FET;GNC;LUFK;MGM;O;PNM;PWER;TFM;XLNX;EFX;GILD;HP;HAL;CLF;RVBD From The Last 14 Days
Check below for free stories on ATML;CRL;CRK;CY;FET;GNC;LUFK;MGM;O;PNM;PWER;TFM;XLNX;EFX;GILD;HP;HAL;CLF;RVBD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 8, 2014
08:49 EDTCRLCharles River Labs pullback creates an interesting set-up, says RW Baird
Subscribe for More Information
05:39 EDTORealty Income initiated with an Underweight at Morgan Stanley
Subscribe for More Information
April 7, 2014
17:01 EDTTFMWhole Foods price target raised to $70 from $62 at UBS
Subscribe for More Information
16:01 EDTMGMOptions Update; April 7, 2014
Subscribe for More Information
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
08:31 EDTGILDGilead announecs FDA priority review designation for Ledipasvir/Sofosbuvir
Gilead Sciences announced that the U.S. Food and Drug Administration has granted priority review to the company’s New Drug Application for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults. Gilead filed the NDA for LDV/SOF on February 10, and the FDA has set a target action date under the Prescription Drug User Fee Act of October 10. The FDA has also assigned LDV/SOF a Breakthrough Therapy designation.
April 4, 2014
09:36 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA MU GNK AMZN FB GILD MA NFLX
April 3, 2014
10:00 EDTXLNXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
07:27 EDTXLNXXilinx initiated with an Outperform at FBR Capital
Subscribe for More Information
April 2, 2014
18:51 EDTCYOn The Fly: After Hours Movers
Subscribe for More Information
16:32 EDTGILDGilead Phase 3 sofosbuvir study meets primary efficacy endpoint
Gilead Sciences announced topline results from a Phase 3 clinical trial in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin for the treatment of genotype 2 chronic hepatitis C virus infection. The study met its primary efficacy endpoint of superiority compared to a predefined historical control sustained virologic response rate. In the study, 97% of genotype 2 HCV-infected patients receiving 12 weeks of an all-oral regimen of sofosbuvir plus RBV achieved a sustained virologic response 12 weeks after completing therapy. Based on these trial results, Gilead anticipates submitting a New Drug Application for sofosbuvir to the Japanese Pharmaceutical and Medical Devices Agency by mid-2014
16:05 EDTXLNXXilinx assumed with a Neutral at Piper Jaffray
Subscribe for More Information
16:03 EDTCYCypress Semiconductor sees Q1 revenue exceeding high-end of $169M-$171M range
Consensus $165M. The company said its Q1 was strong and expects revenue to exceed the higher end of the range of prior guidance with revenue in the $169M-$171M. The company also said, "We have a solid design win pipeline that will feed our revenue growth through Q2."
16:02 EDTCYCypress Semiconductor CFO Buss to retire
Cypress Semiconductor announced that Brad Buss, executive VP and CFO, is retiring from Cypress after eight years of service. He will remain EVP and CFO through June 1, after which Thad Trent, currently VP of Finance, will assume the role of EVP and CFO. Buss will then continue on a part-time basis, assisting in the transition through September 1, after which he will become a non-employee advisor to the board and the CEO through April 30, 2015.
13:49 EDTRVBDSilver Peak confirms patent win against Riverbed, seeks permanent injunction
Subscribe for More Information
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
09:13 EDTEFXEquifax announces alliance with IHS Automotive
Equifax announced the strengthening of their recent strategic alliance with IHS Automotive. This alliance creates a value proposition for the automotive market and allows both organizations the opportunity to bring insights that empower critical business decisions for automotive lenders, dealers and manufacturers. With the announcement of a formal alliance, Equifax is also releasing its first jointly developed product with IHS Automotive, Equifax Lost Sales Analysis. This solution captures auto loan application data and uses it to produce analysis of where lenders lost out on deals to their competitors. Lenders are also able to assess how missed opportunities are performing and whether the original offers could have been more competitive.
06:21 EDTGILDGilead shares attractive at current levels, says Citigroup
Citigroup views shares of Gilead as "cheap" at current levels and keeps a Buy rating on the name with a $96 price target. Citi expects Gilead to generate $117B in free cash flow over the next 10 years and have $100B by 2023.
05:42 EDTCLFCliffs Natural announces voluntary delisting from Euronext Paris
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use